Pharmaceuticals, Biotechnology and Life Sciences
Futura Medical has filed a new formulation patent for its topical gel for the treatment of erectile dysfunction, with the UK Intellectual Property Office in connection with MED2002.
Futura Medical’s pivotal efficacy study of MED2002, a novel gel for the treatment of erectile dysfunction (ED) is underway and recruitment of patients for the study is proceeding well, with 118 patients having enrolled in the study to date.
Quantum Pharma Plc has announced that it had signed an exclusive agreement with Futura Medical plc the healthcare company which is focused on advanced transdermal technology, to manufacture and make available MED2002, Futura’s novel treatment for erectile dysfunction, as an unlicensed medicine (special) in the UK (the “Agreement”).